Receipt date: 03/11/2011

PTO/SB/06a (04-07)
Approved for use through 9/30/2007. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary) Sheet 1 of 2
 to regord to a caleston of information unless 4 displays a suit ONS cored number

 Confirmation Number
 21.98
 48
 47

 Application Number
 99/966,447
 99/966,419
 59/966,419

 First Named Invontor
 David Christian Lentz
 670up Art Unit
 373

 Examinor Name
 M. K. Ryckman

 Attorney Docket Number
 CRO-9957

	U.S. Patent Document		ment			
Examiner Initials	Cite No.1	Number	Kind Code ² (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document mm-dd-yyyy	Pages, Columns, Lines, where relevant passages of relevant figures appear
		3,178,399		Lo, E. S.,	04-13-1965	
		4,564,013		Lilenfeld, R., et al.	01-14-1986	
		4,816,339		Tu, R. H., et al.	03-28-1989	
		5,516,781	Α	Morris, R, et al.	05-14-1996	
		5,563,146	Α	Morris, R., et al.	10-08-1996	
		5,603,894	A	Aikus, A., et al.	02-18-1997	
		5,824,048	Α	Tuch, R., J.	10-20-1998	
		5,837,313	А	Ding, N., et al.	11-17-1998	
		5,962,516	А	Qi, Y., et al.	10-05-1999	
		6,273,913	B1	Wright, C., et al.	08-14-2001	
		6,335,029	B1	Kamath, K., et al.	01-01-2002	

FOREIGN PATENT DOCUMENTS Foreign Patent Document Date of Publication Pages, Columns, Lines, of Cited Document where relevant Name of Patentee or Cit passages or relevant T^6 mm-dd-yyyy Applicant of Cited Document Initials Office³ Number⁴ KindCode⁵ figures appear Νo FR 2,785,812 Α1 Commissariat a 11-16-1998 U.S. 6,517,858 L'Energie Atomique (Paris) JΡ 01-506176 Α Iowa-India Investments U.S. 6.214.040 Company JP. 5-305092 Cook Incorporated U.S.5,755,777 WO 97/35575 A1 Novartis AG 10-02-1997 WO 98/38687 Α1 Elf Atochem North 09-03-1998 America, Inc.

Examiner Signature /Melissa Ryckman/ (04/28/2011) Date Considered

*EXAMMEET initial if reference confidences, wherefire or not outdoor is in conformance with MEPE 030. Date line through clastion if not in conformance and not considered, include copy of this form with the extormanication to applicant. Application strong plant classified explant on martier (cotional). See Kinds Code of U.S. Patient Documents at www.neuron.com/sea/back/. Either Office that issued the document, by the two-leter code (MPDO Standard ST.3), 4 For Japanese patient counters, the indication of the year of the represent must proceed the estimal number of the patient document, should of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. Applicant is to place a check mark here if English language Pransistion is attacked.

This collection of information is required by 37 CFR 1,97 and 1,98. The information required to obtain or retain a benefit by the public which is to file (and by the USPP10 to process) an application. Confidentially is gowered by 35 US. 122 and 37 CFR 1,14. This collection is estimated to take 5 hot complete, including gathering, preparing, and submitting the completed application to the USPI0. Time will vary depending upon the individual case. Any comments on the amount of three you are required to complete his form should be sent to the Cultific information Office, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, V.A. 2231-1450, D. ON OT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND 107: Commissioner for Patents, P.O. Box 1450, Alexandria, V.A. 2231-1450, U.A. 2231-1450.

Receipt date: 03/11/2011

PTO/SB/08a (04-07) Approved for use through 9/30/2007. OMB 0651-0031 PTO/SB/08b (04-07)

Approved for use through 9/30/2007 OMB 0661-0031 U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary) Sheet 2 of 2

to respond to a collection of information unless it displays a valid OMB control number				
Confirmation Number	2148			
Application Number	09/966,447			
Filing Date	September 28,2001			
First Named Inventor	David Christian Lentz			
Group Art Unit	3773			
Examiner Name	M. K. Ryckman			
Attorney Docket Number	CRD-0957			

		OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item	
Examiner's Initials*	Cite No.1	(book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T²
		HIDALGO, M., et al. "The Rapamycin-Sensitive Signal Transduction Pathway as a Target for Cancer Therapy", Onogene (2000) Vol. 19,p. 6680-6686	
		LUENGO, J., et al. "Structure-Activity Studies of Rapamycin Analogs: Evidence that the C-7 Methoxy Group is Part of the Effector Domain and Positioned at the FKBP12-FRAP Interface", Chemistry & Biology (1995) Vol. 2,pp. 471-481	
		TOURNUT, C., et al. "Thermoplastic Copolymers of Vinylidene Fluoride", Modern Fluoropolymers (1997), Chapter 31, pp. 577-596	
		ZARAGOZA, D., et al. "Rapamycin Induces the G ₃ Program of Transcriptional Repression in Yeast by Interfering with the TOR Signaling Pathway", Molecular and Cellular Biology (1998) Vol. 18, No. 8, pp. 4463-4470	

Examiner Signature	/Melissa Ryckman/ (04/28/2011)	Date Considered	

^{*}EXAMINER: Initial if reference considered, whether or not obtation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next commiscation to applicate the representation of the repres

¹ Applicant's unique obtainn designation number (potchnal). Applicant is to place a check mark here if English language Translation is attached. This collection of Information is required by 7 CRF 13 7 and 135. The information required to obtain or retain a benefit by the public which is to 5 fee (and by the UBPT 0 or process) an application. Confidentially go governed by \$5.0.S.C. 122 and 37 CRF 1.14. This collection is estimated to take 2 hours to complete, michigal patienting, preparing and submitting fine completed application to the USPT 0. The met why deplecting on the advisual complete, michigal patients, preparing and submitting fine completed application to the USPT 0. The met why deplecting on the advisual complete, michigal patients, preparing out the advisual control of the USPT 0. The method with the process of the complete application to the USPT 0. The Michigal Complete Co